Soluble form of carbonic anhydrase IX (s-CA IX), assays to...

Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C436S064000, C530S350000, C530S387300

Reexamination Certificate

active

07833728

ABSTRACT:
Disclosed herein is the discovery of a soluble MN/CA IX (s-CA IX) in body fluids, such as, urine and serum. Said s-CA IX comprises the extracellular domain of CA IX or portions thereof. The predominant s-CA IX species is the extracellular domain comprising a proteoglycan-like (PG) domain and carbonic anhydrase (CA) domain, and having a molecular weight of about 50/54 kilodaltons (kd) upon Western blot. A smaller s-CA IX form of about 20 to about 30 kd comprising the CA domain or parts thereof, not linked to the PG domain, has also been found in body fluids. Diagnostic/prognostic methods for precancer and cancer that detect or detect and quantitate said s-CA IX in body fluids, are described. Also disclosed herein is the coexpression of CA IX and HER-2
eu/c-erbB-2 that provides parallel, alternative and potentially synergistic diagnostic/prognostic and therapeutic strategies for precancer and cancer. Further disclosed are new MN/CA IX-specific antibodies generated from MN/CA IX-deficient mice, preferably monoclonal antibodies and immunoreactive fragments and engineered variants thereof. Such new MN/CA IX-specific antibodies, fragments and variants are useful diagnostically/prognostically and therapeutically for cancer and precancer. Particularly preferred are the new monoclonal antibodies, fragments and variants that are specific for the non-immunodominant epitopes of MN/CA IX, which antibodies are, among other uses, useful to detect soluble MN/CA IX (s-CA IX) in body fluids, alone but preferably in combination with antibodies specific to the immunodominant epitopes of MN/CA IX, for example, in a sandwich assay.

REFERENCES:
patent: 4968603 (1990-11-01), Slamon et al.
patent: 5387676 (1995-02-01), Zavada et al.
patent: 5401638 (1995-03-01), Carney et al.
patent: 5955075 (1999-09-01), Zavada et al.
patent: 5972353 (1999-10-01), Zavada et al.
patent: 5981711 (1999-11-01), Zavada et al.
patent: 5989838 (1999-11-01), Zavada et al.
patent: 6004535 (1999-12-01), Zavada et al.
patent: 6027887 (2000-02-01), Zavada et al.
patent: 6051226 (2000-04-01), Zavada et al.
patent: 6069242 (2000-05-01), Zavada et al.
patent: 6093548 (2000-07-01), Zavada et al.
patent: 6204370 (2001-03-01), Zavada et al.
patent: 6297041 (2001-10-01), Zavada et al.
patent: 6297051 (2001-10-01), Zavada et al.
patent: 6770438 (2004-08-01), Zavada et al.
patent: 6774117 (2004-08-01), Zavada et al.
patent: WO 93/18152 (1993-09-01), None
patent: WO 95/34650 (1995-12-01), None
patent: WO 00/24913 (2000-05-01), None
patent: WO 2004/017923 (2004-03-01), None
patent: WO 2008/103327 (2008-08-01), None
Barathova et al. (Br. J. Cancer. Jan. 15, 2008; 98 (1):129-136).
De Schutter et al. (BMC Cancer. Apr. 25, 2005; 5: 42; published on the Internet; pp. 1-11).
Holotnakova et al. (Pflugers Arch. May 2008; 456 (2): 323-337).
Vordermark et al. (Int. J. Radiat. Oncol. Biol. Phys. Mar. 15, 2005; 61 (4): 1197-1207).
Zavada et al. (Br. J. Cancer. Sep. 15, 2003; 89 (6): 1067-1071).
Zavadora et al. (Oncol. Rep. May 2005; 13 (5): 977-982).
Roessler et al. (Mol. Cell. Prot. 2006; 5 (11): 2092-2101).
Roessler et al. (Clin. Can. Res. 2005; 11 (18): 6550-6557).
Zolg et al. (Mol. Cell. Prot. 2004; 3 (4): 345-354).
Rae et al. (International Journal of Cancer 2000; 88: 726-732).
Ward (Developmental Oncology 1985; 21: 91-106).
Critchfield (Disease Markers 1999; 15: 108-111).
Sidransky (Science 1997; 278: 1054-1058).
Tockman et al. (Cancer Research 1992; 52: 2711s-2718s).
Leibovich et al. (J. Clin. Oncol. Oct. 20, 2007; 25 (3): 4757-4764).
Chia et al. (J. Clin. Oncol. Aug. 15, 2001; 19 (16): 3660-3668).
Watson et al. (Br. J. Cancer. 2003; 88: 1065-1070).
Zavada et al. (Br. J. Cancer. Sep. 2003; 89 (15): 1067-71).
Hyrsl et al. (Neoplasma. 2009; 56 (4): 298-302).
Li et al. (Biochem. Biophys. Res. Commun. Aug. 28, 2009; 386 (3): 488-92).
Zhou et al. (Urology. Feb. 2010; 75 (2): 257-61).
Airley et al., “Glucose Transporter Glut-1 Expression Correlates with Tumor Hypoxia and Predicts Metastasis-free Survival in Advanced Carcinoma on the Cervix,”Clinical Cancer Research, 7: 928-934 (Apr. 2001).
Bander et al., “Renal cancer imaging with monoclonal antibody G250,”J. Urol., 155 (5 Suppl.): 583A (Abstract 1088) (1996).
Chia et al., “Prognostic significance of a novel hypoxia- regulated marker, carbonic anhydrase IX, in invasive breast carcinoma,”J. Clin. Oncol., 19(16): 3660-3668 (Aug. 15, 2001).
Giatromanolaki et al., “Expression of Hypoxia-inducible Carbonic Anhydrase-9 Relates to Angiogenic Pathways and Independently to Poor Outcome in Non-Small Cell Lung Cancer,”Cancer Research, 61(21): 7992-7998 (Nov. 1, 2001).
Griffiths et al., “The macrophate—a novel system to deliver gene therapy to pathological hypoxia,”Gene Therapy, 7: 255-262 (2000).
Horton, J., “Trastuzumab Use in Breast Cancer: Clinical Issues,”Cancer Control, 9(6): 499-507 (2002).
Ivanov et al., “Expression of Hypoxia-Inducible Cell-Surface Transmembrane Carbonic Anhydrases in Human Cancer,”American Journal of Pathology, 158(3): 905-919 (Mar. 2001).
Kaluz et al., “Lowered Oxygen Tension Induces Expression of the Hypoxia Marker MN/Carbonic Anhydrase IX in the Absence of Hypoxia-Inducible Factor I Stabilization: A Role for Phosphatidylinositol 3′-Kinase,”Cancer Research, 62: 4469-4477 (Aug. 1, 2002).
Kivela et al., “Expression of transmembrane carbonic anhydrase isoenzymes IX and XII in normal human pancreas and pancreatic tumours,”Histochemistry and Cell Biology, 114(3): 197-204 (2000).
Kuter, I., “Breast Cancer,”The Oncologist, 6: 338-346 (2001).
Lieskovska et al., “Study of in vitro conditions modulating expression of MN/CA IX protein in human cell lines derived from cervical carcinoma,”Neoplasma, 46(1): 17-24 (1999).
Loncaster et al., “Carbonic Anhydrase (CA IX) Expression, a Potential New Intrinsic Mark of Hypoxia: Correlations with Tumor Oxygen Measurements and Prognosis in Locally Advanced Carcinoma of the Cervix,”Cancer Res, 61(17): 6394-6399 (Sep. 1, 2001).
Oosterwijk and Debruyne, “Radiolabeled monoclonal antibody G250 in renal-cell carcinoma,”World Journal of Urology, 13: 186-190 (1995).
Opavsky et al., “Human MN/CA9 Gene a Novel Member of the Carbonic Anhydrase Family: Structure and Exon to Protein Domain Relationships,”Genomics, 33: 480-487 (1996).
Parkkila et al., “Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in vitro,”PNAS(USA), 97(5): 2220-2224 (Feb. 29, 2000).
Pastorek et al., “Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment,”Oncogene, 9: 2877-2888 (1994).
Pastorekova et al., “A Novel Quasi-viral Agent, MaTu, Is a Two-Component System,”Virology, 187: 620-626 (1992).
Pastorekova et al., “Carbonic Anhydrase IX, MN/CA IX: Analysis of Stomach Complementary DNA Sequence and Expression in Human and Rat Alimentary Tracts,”Gastroenterology, 112: 398-408 (1997).
Revillion et al., “ERBB2Oncogene in Human Breast Cancer and its Clinical Significance,”Euro J. Cancer, 34: 791-808 (1998).
Steffens et al., “Targeting of Renal Cell Carcinoma with Iodine-131-Labeled Chimeric Monoclonal Antibody G250,”Journal of Clinical Oncology, 15(4): 1529-1537 (Apr. 1997).
Steffens et al., “RadioImmunotherapy with 1311-cG250 Monoclonal antibody in Patients with Metastasized RCC, Phase I/II Study,”Journal of Urology, 159 (5 Suppl.): Abstract No. 562 (May 1998).
Teicher et al., “A Carbonic Anhydrase Inhibitor as a Potential Modulator of Cancer Therapies,”Anticancer Research, 13: 1549-1556 (1993).
Trikha et al., “Monoclonal antibodies as therapeutics in oncology,”Current Opinion in Biotechnoogy, 13(6): 609-614 (2002).
Turner et al., “MN Antigen Expression in Normal, Preneoplastic, and Neoplastic Esophagus: a Clinicopathological Study

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Soluble form of carbonic anhydrase IX (s-CA IX), assays to... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Soluble form of carbonic anhydrase IX (s-CA IX), assays to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Soluble form of carbonic anhydrase IX (s-CA IX), assays to... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4152382

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.